Argenx reports positive topline data from adhere study of vyvgart hytrulo in patients with chronic inflammatory demyelinating polyneuropathy

Study met primary endpoint (p=0.000039); vyvgart® hytrulo demonstrated 61% reduction (hr: 0.39 95% ci: 0.25; 0.61) in risk of relapse versus placebo igg autoantibodies shown to play significant role in underlying cidp disease biology favorable safety and tolerability profile consistent with previous clinical trials and confirmed safety profile of vyvgart® conference call scheduled for today, july 17, 2023 at 8:30am et (2:30pm cet) regulated information – inside information amsterdam, the netherlands – july 17 , 2023 – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the adhere study evaluating vyvgart hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating polyneuropathy (cidp). the study met its primary endpoint (p=0.000039), demonstrating a significantly lower risk of relapse with vyvgart hytrulo compared to placebo.
ARGX Ratings Summary
ARGX Quant Ranking